Temporal Concept
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024
Scion Life Sciences Emerges with $310M Fund to Nurture Innovative Biotechnology Startups
Scion, Scion Life Sciences, Investments, Mature
Amgen’s obesity drug takes the weight off and may keep it off, too, early data suggest
Obesity, MariTide, Weight Loss, Source, Amgen’s, weight off
With subpar sales for Leqembi, Eisai delays Alzheimers patient goal deadline
Leqembi, Alzheimer’s Disease, Eisai, subpar sales
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal
Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk
Holdings, Nordisk, deal, Acquisition (action), Investments
Promising Vertex Pain Med Points to New Era for Analgesics
historical period, Analgesics, Opioid, VX-548, Analgesics, Effectiveness, aspects of adverse effects
Eli Lilly says its potential gene therapy ‘restored hearing’ in 11-year-old boy
Hearing, Eli, Boys, 11-year-old
Lillys Investigational Gene Therapy Restores Hearing in First Treated Patient
Hearing, Treating, gene therapy, AK-OTOF